-
New Jersey / NJ Vioxx Trial: Humeston Case Goes to Jury After Closing Arguments
Humeston v. Merck Verdict: Will The Jury Weigh In For The Plaintiff or Defense? Today, after a seven-week trial, a New Jersey state court jury in the Humeston v. Merck Vioxx case should hear…
-
FDA Probably Will Not Require Longer Studies Of New Psychiatric Drugs
Advisory Panel Rejects FDA Proposal: Good Idea, But Wrong Approach In late October 2005 an FDA advisory panel rejected the agency’s recent proposal that would have required the drug companies to do longer-term studies…
-
“Off-label” Prescribing of Psychosis Drugs For Alzheimer’s Has Risks
Careful Consideration Needed When Prescribing Zyprexa or Risperdal for Alzheimer’s-related Dementia Elderly patients with Alzheimer’s disease who are prescribed antipsychotic drugs such as Zyprexa and Risperdal have a higher risk of dying than patients…
-
Public Citizen Petitions FDA To Add Black-Box Warning On Impotence Drugs
Erectile Dysfunction Drugs Viagra, Cialis, and Levitra Linked to NAION Vision Loss In mid-October 2005 the consumer-advocacy group Public Citizen petitioned the FDA to add a "black-box" warning to the labels of Pfizer Inc.’s…
-
After Two-year Search, FDA Names New Director For Office of Drug Safety
FDA Scientist Gerald Dal Pan Will Be Director of FDA Drug-Safety Office In October 2005 the FDA named staff scientist Gerald Dal Pan its new director of the agency’s Office of Drug Safety. This…
-
FDA Wants Longer Studies Done Before Approving New Psychiatric Drugs
Will The FDA Stand Its Ground Against Big Pharma On This Change In Course? Leila Abboud and Anna Wilde Mathews, of The Wall Street Journal ("WSJ"), reported on October 18, 2005 that the FDA…
